-
-
-
-
-
-
-
Agile Therapeutics Announces FDA Extension of Twirla® NDA Review Period
-
-
-
-
-
-
-
Agile Therapeutics (AGRX) Provides Twirla Update, Other Recent Corporate Developments
-
-
-
-
-
-
-
Agile Therapeutics Appoints Chief Financial Officer
-
-
-
-
-
-
-
Agile Therapeutics (AGRX) Announces NDA Resubmission to FDA for Transdermal Low-Dose Contraceptive Patch, Twirla
-
-
-
-
-
-
-
Agile Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results
-
-
-
-
-
-
-
Agile Therapeutics (AGRX) Provides Regulatory Update and Reiterates Cash Guidance
-
-
-
-
-
-
-
Agile Therapeutics Reports Third Quarter 2018 Financial Results
-
15,404 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

